IMPROVE™ observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus

Abstract

The IMPROVE™ study is the largest observational study of therapy in Type 2 diabetes mellitus to date. It is a multinational study investigating the safety and efficacy of biphasic insulin aspart 30/70 (BIAsp 30) in the routine management of patients with Type 2 diabetes mellitus. Five published reports on this study have provided baseline demographic information for patients receiving BIAsp 30 in eight countries, information on the safety and efficacy outcomes for those patients and analyses of three subgroups of patients who were insulin-naive, receiving basal insulin or receiving biphasic human insulin before the start of the study. These subanalyses provided information on the optimal prescribing and dosing strategies when starting treatment with BIAsp 30 in these groups of patients in normal clinical practice. The study extends the results from clinical trials of BIAsp 30 and confirms its benefits in routine care, in a large, global, heterogeneous patient population.

Keywords::

• biphasic insulin aspart 30
• dosing regimen
• observational study
• switching treatment
• Type 2 diabetes mellitus

Financial & competing interests disclosure

Paul Valensi has served as chairman to the advisory board of the IMPROVE™ study and has given lectures for Novo Nordisk. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors gratefully acknowledge writing and editorial assistance from Watermeadow Medical, Witney, UK, funded by Novo Nordisk.